bendroflumethiazide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
diuretics, chlorothiazide derivatives 305 73-48-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • bendroflumethiazide
  • bendrofluazide
  • benzhydroflumethiazide
  • benzidroflumetiazide
  • benzydroflumethiazide
  • benzylhydroflumethiazide
  • benzylrodiuran
A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810)
  • Molecular weight: 421.41
  • Formula: C15H14F3N3O4S2
  • CLOGP: 1.73
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 3
  • TPSA: 118.36
  • ALOGS: -3.29
  • ROTB: 4
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2.50 mg O
2.50 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.11 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 21 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.79 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 90 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 2.035 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 70.146 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 1.259 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 2.133 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 6.210 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 12.450 % High 1
herg hERG pIC50 4.300 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.858 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 6.592 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 4.930 % High 1
kinase-safety-class ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,EGFR,EIF2AK3,ERBB2,GRK2,ITK,MAPK10,MAPK7,MAPKAPK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CG,PRKDC,TEK 23
kinase-selectivity-class AXL,GRK2,MAP2K6,PDK1,PDK4 5
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 6.383 High 1
mh-clint Mouse hepatocyte intrinsic clearance 17.298 High 1
mppb Mouse plasma protein binding (% unbound) 4.470 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 10.593 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 1
pppb Pig plasma protein binding (% unbound) 10.870 % High 1
rh-clint Rat hepatocyte intrinsic clearance 11.967 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 54.540 % High 1
rppb Rat plasma protein binding (% unbound) 6.040 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 105.196 uM High 1

Approvals:

DateAgencyCompanyOrphan
Dec. 7, 1959 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cardiospasm 314.90 28.06 80 15179 3366 90609822
Palmoplantar keratoderma 313.51 28.06 80 15179 3427 90609761
Lip swelling 309.22 28.06 144 15115 38466 90574722
Tension headache 303.97 28.06 92 15167 7417 90605771
Pruritus genital 297.37 28.06 81 15178 4477 90608711
Sleep terror 294.36 28.06 80 15179 4384 90608804
Atrial tachycardia 279.88 28.06 82 15177 5908 90607280
Carotid artery occlusion 266.59 28.06 80 15179 6262 90606926
Immunisation 240.31 28.06 59 15200 2154 90611034
Anosmia 231.97 28.06 80 15179 9768 90603420
Hyponatraemia 228.25 28.06 185 15074 133353 90479835
Hallucination 213.82 28.06 135 15124 65824 90547364
Facial pain 212.80 28.06 81 15178 13101 90600087
Subarachnoid haemorrhage 205.42 28.06 86 15173 17818 90595370
Intentional product misuse 198.77 28.06 145 15114 89459 90523729
Pain of skin 197.18 28.06 81 15178 16001 90597187
Blindness 184.87 28.06 90 15169 26478 90586710
Diplopia 184.12 28.06 92 15167 28622 90584566
Vasculitis 179.62 28.06 84 15175 22609 90590579
Drug ineffective 175.77 28.06 16 15243 1384282 89228906
Ventricular tachycardia 172.81 28.06 84 15175 24624 90588564
Amyloid arthropathy 168.36 28.06 42 15217 1638 90611550
Pulmonary pain 166.31 28.06 53 15206 5061 90608127
Eye pruritus 165.73 28.06 86 15173 28941 90584247
Muscle twitching 162.44 28.06 80 15179 24122 90589066
Angioedema 152.99 28.06 109 15150 64767 90548421
Palpitations 141.68 28.06 143 15116 136585 90476603
Tinnitus 134.09 28.06 86 15173 43016 90570172
Transient ischaemic attack 129.02 28.06 84 15175 43092 90570096
Disturbance in attention 127.11 28.06 86 15173 47023 90566165
Cognitive disorder 111.81 28.06 93 15166 69314 90543874
Amnesia 106.03 28.06 110 15149 108395 90504793
Rash papular 98.40 28.06 54 15205 20301 90592887
Visual impairment 88.16 28.06 110 15149 132255 90480933
Disturbance in social behaviour 83.25 28.06 30 15229 4158 90609030
Hyperhidrosis 80.91 28.06 107 15152 136198 90476990
Myocardial infarction 80.24 28.06 94 15165 105878 90507310
Dry skin 80.16 28.06 86 15173 87987 90525201
Drug abuse 77.76 28.06 82 15177 82265 90530923
Tachycardia 76.02 28.06 112 15147 157561 90455627
Blood glucose increased 71.29 28.06 84 15175 95162 90518026
Malaise 67.36 28.06 234 15025 585752 90027436
Paranoia 67.27 28.06 36 15223 12872 90600316
Mouth swelling 64.25 28.06 27 15232 5635 90607553
Dehydration 58.70 28.06 112 15147 194335 90418853
Weight increased 58.05 28.06 3 15256 417924 90195264
Infusion related reaction 57.86 28.06 3 15256 416777 90196411
Feeling abnormal 57.63 28.06 102 15157 167133 90446055
Nasopharyngitis 56.30 28.06 3 15256 407101 90206087
Lethargy 56.29 28.06 61 15198 63078 90550110
Heart rate increased 55.55 28.06 81 15178 112821 90500367
Acute kidney injury 54.60 28.06 147 15112 320240 90292948
Vomiting 48.77 28.06 261 14998 788032 89825156
Swelling 45.27 28.06 8 15251 419050 90194138
Agitation 45.01 28.06 56 15203 67042 90546146
Muscular weakness 44.82 28.06 104 15155 206562 90406626
Abnormal behaviour 44.26 28.06 34 15225 22594 90590594
Hepatic enzyme increased 43.35 28.06 5 15254 360731 90252457
Superinfection 42.69 28.06 17 15242 3095 90610093
Ejection fraction decreased 41.87 28.06 35 15224 26218 90586970
Disorientation 41.75 28.06 44 15215 44070 90569118
Sinusitis 40.62 28.06 5 15254 343083 90270105
Nail dystrophy 40.14 28.06 13 15246 1305 90611883
Hypokalaemia 40.13 28.06 76 15183 131040 90482148
Death 39.16 28.06 14 15245 456537 90156651
Duodenal ulcer repair 38.68 28.06 7 15252 54 90613134
Dizziness 36.96 28.06 196 15063 589088 90024100
Condition aggravated 36.72 28.06 28 15231 595517 90017671
Orthostatic hypotension 36.56 28.06 40 15219 41787 90571401
Hypomagnesaemia 36.38 28.06 37 15222 35551 90577637
Drug hypersensitivity 35.27 28.06 17 15242 463592 90149596
Stomatitis 35.11 28.06 3 15256 274695 90338493
Hypersensitivity vasculitis 34.77 28.06 16 15243 4143 90609045
Confusional state 34.13 28.06 142 15117 386063 90227125
COVID-19 33.39 28.06 82 15177 168761 90444427
Duodenogastric reflux 33.34 28.06 7 15252 124 90613064
Femoral neck fracture 33.25 28.06 21 15238 10212 90602976
Cellulitis 33.11 28.06 57 15202 91280 90521908
Swelling face 32.46 28.06 53 15206 81299 90531889
Treatment failure 32.38 28.06 6 15253 303922 90309266
Memory impairment 32.05 28.06 89 15170 197155 90416033
Weight decreased 31.97 28.06 12 15247 379898 90233290
Emotional distress 31.93 28.06 35 15224 36627 90576561
Neutropenic sepsis 30.64 28.06 25 15234 18105 90595083
Back pain 29.90 28.06 119 15140 317056 90296132
Monoclonal B-cell lymphocytosis 29.86 28.06 7 15252 209 90612979
Glossodynia 29.09 28.06 9 15250 321770 90291418
Drug intolerance 28.93 28.06 20 15239 447571 90165617
Peripheral swelling 28.36 28.06 141 15118 412965 90200223
Wound 28.25 28.06 8 15251 302972 90310216
Migraine 28.10 28.06 83 15176 190309 90422879

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cardiospasm 317.14 35.64 77 10321 1830 42609107
Palmoplantar keratoderma 294.48 35.64 75 10323 2179 42608758
Lip swelling 285.24 35.64 123 10275 18930 42592007
Pruritus genital 282.75 35.64 75 10323 2564 42608373
Sleep terror 275.07 35.64 75 10323 2851 42608086
Tension headache 272.67 35.64 77 10321 3337 42607600
Atrial tachycardia 262.34 35.64 78 10320 4062 42606875
Carotid artery occlusion 252.69 35.64 76 10322 4118 42606819
Facial pain 247.23 35.64 75 10323 4185 42606752
Anosmia 236.94 35.64 76 10322 5100 42605837
Immunisation 210.20 35.64 51 10347 1207 42609730
Pain of skin 207.46 35.64 77 10321 8003 42602934
Muscle twitching 199.33 35.64 83 10315 11697 42599240
Subarachnoid haemorrhage 195.65 35.64 87 10311 14385 42596552
Eye pruritus 181.68 35.64 77 10321 11335 42599602
Pericarditis 169.56 35.64 77 10321 13367 42597570
Blindness 165.74 35.64 83 10315 17895 42593042
Rash papular 162.84 35.64 72 10326 11739 42599198
Vasculitis 152.34 35.64 79 10319 18315 42592622
Amnesia 150.50 35.64 91 10307 28346 42582591
Diplopia 139.43 35.64 77 10321 20239 42590698
Angioedema 132.92 35.64 98 10300 42379 42568558
Abdominal discomfort 129.84 35.64 123 10275 75132 42535805
Migraine 125.96 35.64 78 10320 25336 42585601
Hallucination 124.84 35.64 107 10291 57400 42553537
Disturbance in attention 124.06 35.64 82 10316 29784 42581153
Cognitive disorder 116.35 35.64 83 10315 34089 42576848
Transient ischaemic attack 115.00 35.64 82 10316 33657 42577280
Ventricular tachycardia 113.75 35.64 78 10320 30082 42580855
Tinnitus 109.51 35.64 75 10323 28863 42582074
Palpitations 107.15 35.64 93 10305 50704 42560233
Alopecia 106.37 35.64 74 10324 29202 42581735
Visual impairment 99.23 35.64 83 10315 43030 42567907
Intentional product misuse 98.84 35.64 97 10301 61803 42549134
Peripheral swelling 95.86 35.64 114 10284 90156 42520781
Drug ineffective 93.82 35.64 20 10378 630177 41980760
Radiation inflammation 89.85 35.64 25 10373 1023 42609914
Feeling abnormal 87.37 35.64 96 10302 69690 42541247
Abdominal pain upper 83.88 35.64 102 10296 82507 42528430
Memory impairment 82.58 35.64 80 10318 50142 42560795
Pulmonary pain 79.75 35.64 25 10373 1553 42609384
Dry skin 77.60 35.64 76 10322 48262 42562675
Malaise 72.90 35.64 160 10238 211996 42398941
Heart rate increased 69.66 35.64 75 10323 53180 42557757
Blood glucose increased 62.14 35.64 83 10315 73616 42537321
COVID-19 61.29 35.64 105 10293 115843 42495094
Muscular weakness 59.89 35.64 87 10311 83411 42527526
Death 58.68 35.64 21 10377 471164 42139773
Neutropenic sepsis 52.55 35.64 38 10360 15908 42595029
Tachycardia 51.38 35.64 90 10308 100997 42509940
Hyperhidrosis 50.50 35.64 84 10314 90428 42520509
Chest pain 45.31 35.64 103 10295 139427 42471510
Lower respiratory tract infection 45.25 35.64 53 10345 41153 42569784
Hyponatraemia 43.56 35.64 84 10314 101378 42509559
Dehydration 43.12 35.64 102 10296 141665 42469272
Toxicity to various agents 41.48 35.64 4 10394 229132 42381805
Genital pain 40.14 35.64 13 10385 897 42610040
Asthenia 39.43 35.64 10 10388 280783 42330154
Bradyarrhythmia 39.09 35.64 17 10381 2658 42608279
Anxiety 36.79 35.64 86 10312 118474 42492463
Genital ulceration 36.36 35.64 12 10386 879 42610058

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cardiospasm 579.25 27.33 149 25128 4818 110559204
Lip swelling 564.88 27.33 261 25016 50406 110513616
Palmoplantar keratoderma 557.66 27.33 147 25130 5240 110558782
Tension headache 537.29 27.33 162 25115 9456 110554566
Pruritus genital 534.41 27.33 148 25129 6374 110557648
Sleep terror 527.86 27.33 147 25130 6463 110557559
Atrial tachycardia 501.56 27.33 152 25125 9026 110554996
Carotid artery occlusion 478.43 27.33 148 25129 9417 110554605
Anosmia 439.82 27.33 148 25129 12324 110551698
Facial pain 413.60 27.33 149 25128 15190 110548832
Immunisation 408.08 27.33 103 25174 3080 110560942
Pain of skin 385.41 27.33 152 25125 19877 110544145
Subarachnoid haemorrhage 368.74 27.33 165 25112 29537 110534485
Blindness 336.89 27.33 165 25112 36194 110527828
Muscle twitching 335.93 27.33 155 25122 29780 110534242
Eye pruritus 322.52 27.33 155 25122 32620 110531402
Hallucination 317.20 27.33 228 25049 101204 110462818
Vasculitis 309.23 27.33 155 25122 35718 110528304
Diplopia 303.40 27.33 161 25116 41733 110522289
Hyponatraemia 282.84 27.33 296 24981 217357 110346665
Intentional product misuse 274.94 27.33 234 25043 132670 110431352
Ventricular tachycardia 258.34 27.33 154 25123 49855 110514167
Angioedema 255.60 27.33 198 25079 98302 110465720
Disturbance in attention 240.01 27.33 159 25118 61836 110502186
Rash papular 239.88 27.33 120 25157 27519 110536503
Pulmonary pain 235.02 27.33 78 25199 6215 110557807
Amnesia 233.25 27.33 193 25084 105215 110458807
Transient ischaemic attack 233.06 27.33 158 25119 63824 110500198
Drug ineffective 231.86 27.33 36 25241 1520504 109043518
Tinnitus 228.89 27.33 153 25124 60387 110503635
Palpitations 211.11 27.33 219 25058 158993 110405029
Cognitive disorder 209.96 27.33 168 25109 87343 110476679
Visual impairment 172.94 27.33 182 25095 134246 110429776
Amyloid arthropathy 155.60 27.33 42 25235 1638 110562384
Dry skin 153.37 27.33 154 25123 107499 110456523
Blood glucose increased 135.28 27.33 159 25118 132337 110431685
Feeling abnormal 129.61 27.33 182 25095 180529 110383493
Malaise 121.66 27.33 383 24894 671436 109892586
Hyperhidrosis 115.98 27.33 176 25101 187122 110376900
Tachycardia 113.04 27.33 193 25084 226452 110337570
Heart rate increased 110.83 27.33 150 25127 143684 110420338
Myocardial infarction 101.66 27.33 168 25109 191915 110372107
Abdominal discomfort 100.03 27.33 254 25023 393604 110170418
Dehydration 99.47 27.33 206 25071 279305 110284717
Migraine 94.71 27.33 153 25124 171499 110392523
Radiation inflammation 91.45 27.33 25 25252 1023 110562999
Muscular weakness 88.24 27.33 183 25094 248285 110315737
Peripheral swelling 86.86 27.33 245 25032 403789 110160233
Memory impairment 85.65 27.33 158 25119 196786 110367236
COVID-19 84.11 27.33 178 25099 244882 110319140
Weight increased 82.69 27.33 3 25274 419641 110144381
Neutropenic sepsis 82.27 27.33 63 25214 30683 110533339
Lethargy 80.42 27.33 103 25174 93473 110470549
Acute kidney injury 77.04 27.33 318 24959 635112 109928910
Death 76.61 27.33 32 25245 698837 109865185
Abdominal pain upper 72.37 27.33 209 25068 348902 110215120
Disturbance in social behaviour 68.86 27.33 30 25247 5028 110558994
Swelling face 64.67 27.33 92 25185 92229 110471793
Pericarditis 63.73 27.33 149 25128 218965 110345057
Rheumatoid arthritis 56.18 27.33 3 25274 299610 110264412
Dizziness 55.88 27.33 310 24967 697883 109866139
Chest pain 55.87 27.33 201 25076 376174 110187848
Infusion related reaction 55.59 27.33 10 25267 381152 110182870
Hepatic enzyme increased 55.01 27.33 5 25272 320887 110243135
Vomiting 54.46 27.33 375 24902 910300 109653722
Swelling 53.90 27.33 8 25269 351033 110212989
Toxicity to various agents 52.62 27.33 22 25255 480533 110083489
Sinusitis 52.57 27.33 4 25273 296684 110267338
Pruritus 52.51 27.33 267 25010 581293 109982729
General physical health deterioration 52.47 27.33 16 25261 425279 110138743
Mouth swelling 52.46 27.33 28 25249 7326 110556696
Confusional state 52.40 27.33 229 25048 468451 110095571
Weight decreased 51.94 27.33 21 25256 468036 110095986
Back pain 51.59 27.33 194 25083 370802 110193220
Orthostatic hypotension 50.85 27.33 69 25208 66180 110497842
Lower respiratory tract infection 50.77 27.33 146 25131 242960 110321062
Anxiety 45.95 27.33 178 25099 344900 110219122
Paranoia 43.35 27.33 38 25239 22336 110541686
Thrombocytopenia 43.25 27.33 13 25264 348872 110215150
Agitation 42.12 27.33 85 25192 112966 110451056
Drug abuse 39.42 27.33 109 25168 177302 110386720
Drug hypersensitivity 39.22 27.33 28 25249 454062 110109960
Alopecia 39.05 27.33 176 25101 364577 110199445
Condition aggravated 38.67 27.33 68 25209 734768 109829254
Anaemia 38.47 27.33 41 25236 547045 110016977
Nail dystrophy 37.15 27.33 13 25264 1215 110562807
Treatment failure 36.86 27.33 9 25268 277225 110286797
Knee arthroplasty 35.92 27.33 58 25219 64890 110499132
Bradyarrhythmia 35.79 27.33 19 25258 4915 110559107
Genital pain 35.48 27.33 13 25264 1387 110562635
Adverse drug reaction 35.38 27.33 76 25201 105483 110458539
Hypomagnesaemia 34.88 27.33 55 25222 60315 110503707
Pneumonia 34.70 27.33 95 25182 876619 109687403
Duodenal ulcer repair 34.31 27.33 7 25270 77 110563945
Psoriatic arthropathy 33.89 27.33 3 25274 196758 110367264
Dyspnoea 33.48 27.33 393 24884 1106479 109457543
Hypertension 32.85 27.33 41 25236 510043 110053979
Inappropriate schedule of product administration 32.76 27.33 4 25273 203633 110360389
Disorientation 32.33 27.33 58 25219 70613 110493409
Insomnia 32.09 27.33 165 25112 360425 110203597
Liver function test abnormal 32.07 27.33 57 25220 68893 110495129
Completed suicide 31.96 27.33 8 25269 242373 110321649
Hypokalaemia 31.91 27.33 103 25174 182345 110381677
Impaired healing 31.32 27.33 4 25273 196713 110367309
Mixed dementia 30.33 27.33 8 25269 285 110563737
Drug intolerance 30.23 27.33 29 25248 406483 110157539
Lid lag 29.56 27.33 7 25270 159 110563863
Wound 28.57 27.33 9 25268 234428 110329594
Duodenogastric reflux 27.86 27.33 7 25270 205 110563817
Genital ulceration 27.82 27.33 12 25265 1963 110562059
Superinfection 27.80 27.33 17 25260 5746 110558276
White blood cell count decreased 27.61 27.33 9 25268 229381 110334641
Abnormal loss of weight 27.39 27.33 21 25256 10236 110553786

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C03AA01 CARDIOVASCULAR SYSTEM
DIURETICS
LOW-CEILING DIURETICS, THIAZIDES
Thiazides, plain
ATC C03AB01 CARDIOVASCULAR SYSTEM
DIURETICS
LOW-CEILING DIURETICS, THIAZIDES
Thiazides and potassium in combination
ATC C03EA13 CARDIOVASCULAR SYSTEM
DIURETICS
DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION
Low-ceiling diuretics and potassium-sparing agents
FDA CS M0471776 Thiazides
FDA PE N0000175359 Increased Diuresis
FDA EPC N0000175419 Thiazide Diuretic
CHEBI has role CHEBI:35498 diuretic
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35674 antihypertensive agent
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D004232 Diuretics
MeSH PA D045283 Natriuretic Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D049993 Sodium Chloride Symporter Inhibitors

Related Drugs by ATC class:

C03AA Thiazides, plain 9 drugs
chlorothiazidecyclopenthiazidecyclothiazidehydrochlorothiazidehydroflumethiazidemebutizidemethylclothiazidepolythiazidetrichlormethiazide
C03AB Thiazides and potassium in combination 8 drugs
chlorothiazidecyclopenthiazidecyclothiazidehydrochlorothiazidehydroflumethiazidemethylclothiazidepolythiazidetrichlormethiazide
C03EA Low-ceiling diuretics and potassium-sparing agents 9 drugs
altizidebutizidechlortalidonecyclopenthiazideepitizidehydrochlorothiazidemebutizidemetolazonetrichlormethiazide

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Anuria contraindication 2472002 DOID:2983
Bronchospasm contraindication 4386001
Hypercholesterolemia contraindication 13644009
Complete atrioventricular block contraindication 27885002
Depressive disorder contraindication 35489007
Hyperuricemia contraindication 35885006 DOID:1920
Anaphylaxis contraindication 39579001
Hypokalemia contraindication 43339004
Sinus bradycardia contraindication 49710005
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Sympathectomy contraindication 57071006
Acute nephropathy contraindication 58574008
Hypercalcemia contraindication 66931009 DOID:12678
Hyperparathyroidism contraindication 66999008 DOID:13543
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Oliguria contraindication 83128009
Pulmonary emphysema contraindication 87433001
Cardiogenic shock contraindication 89138009
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Hypomagnesemia contraindication 190855004
Partial atrioventricular block contraindication 195039008
Decompensated cardiac failure contraindication 195111005
Acute pancreatitis contraindication 197456007 DOID:2913
Disease of liver contraindication 235856003 DOID:409
Raynaud's phenomenon contraindication 266261006
Neonatal hyperbilirubinemia contraindication 281610001
Pregnancy, function contraindication 289908002
Severe chronic obstructive pulmonary disease contraindication 313299006
Right ventricular failure contraindication 367363000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.79 acidic
pKa2 10.52 acidic
pKa3 1.03 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Solute carrier family 12 member 3 Transporter INHIBITOR A2 8.30 WOMBAT-PK CHEMBL
Carbonic anhydrase 2 Enzyme Kd 5.77 CHEMBL
Carbonic anhydrase 1 Enzyme WOMBAT-PK
Carbonic anhydrase 4 Enzyme WOMBAT-PK
Calcium-activated potassium channel subunit alpha-1 Ion channel WOMBAT-PK

External reference:

IDSource
4017612 VUID
N0000145992 NUI
D00650 KEGG_DRUG
1369 RXNORM
C0004975 UMLSCUI
CHEBI:3013 CHEBI
CHEMBL1684 ChEMBL_ID
D001539 MESH_DESCRIPTOR_UI
DB00436 DRUGBANK_ID
2315 PUBCHEM_CID
7122 IUPHAR_LIGAND_ID
994 INN_ID
5Q52X6ICJI UNII
3020 MMSL
4252 MMSL
d00641 MMSL
4017612 VANDF
002297 NDDF
387520007 SNOMEDCT_US
91135008 SNOMEDCT_US
5Q52X6ICJI INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Nadolol and Bendroflumethiazide HUMAN PRESCRIPTION DRUG LABEL 2 0115-5311 TABLET 5 mg ORAL ANDA 25 sections
Nadolol and Bendroflumethiazide HUMAN PRESCRIPTION DRUG LABEL 2 0115-5322 TABLET 5 mg ORAL ANDA 25 sections